Frequency of Hprt mutant lymphocytes and micronucleated erythrocytes in p53-haplodeficient mice treated perinatally with AZT and AZT in combination with 3TC

被引:12
作者
Dobrovolsky, Vasily N.
Shaddock, Joseph G.
Mittelstaedt, Roberta A.
Bishop, Michelle E.
Lewis, Sherry M.
Lee, Fei W.
Aidoo, Anane
Leakey, Julian E. A.
Dunnick, June K.
Heflich, Robert H.
机构
[1] Natl Ctr Toxicol Res, US FDA, Div Genet & Reprod Toxicol, Jefferson, AR 72079 USA
[2] Natl Ctr Toxicol Res, Off Sci Coordinat, Jefferson, AR 72079 USA
[3] Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA
关键词
nucleoside analog reverse transcriptase inhibitors; reticulocytes; normochromatic erythrocytes; transplacental exposure; neonatal exposure;
D O I
10.1002/em.20280
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Azidothymidine (AZT) is a nucleoside reverse transcriptase inhibitor (NRTI) that is used for reducing mother-to-child transmission of human immunodeficiency virus 1. Combinations of AZT and 3'-thiacyticline (3TC) are even more effective than AZT alone. AZT, however, is a mutagen and carcinogen in rodent models and 3TC can increase the genotoxicity of AZT. Since p53 plays a key role in human and mouse tumorigenesis, p53-haplodeficient mice are currently being evaluated as a model for assessing the carcinogenicity of perinatal exposure to NRTIs. In the present study, male C57BL/6 p53(+/+) and p53(-/-) mice were mated with C3H p53(+/+) females; the pregnant females were treated on gestation day 12 through parturition with 40, 80, and 160 mg/kg of AZT or a combination of 160 mg/kg AZT and 100 mg/kg 3TC (AZT-3TC); the p53(+/+) and p53(+/-) offspring were treated daily after birth through postnatal day (PND) 28. The frequencies of micronucleated reticulocytes (MN-RETs) and micronucleated normochromatic erythrocytes (MN-NCEs) were determined on PNDI, PND 10, and PND28; the frequency of Hprt mutant lymphocytes was measured on PND28. The frequencies of MN-RETs and MN-NCEs were increased in treated animals at all time points; there were no differences in the responses of p53(+/+) and p53(+/-) animals treated with identical doses of NRTIs. After correction for clonal expansion, both AZT and AZT-3TC treatments induced small but significant increases in the frequency of Hprt mutant lymphocytes in p53(+/-) mice, but not in p53(+/+) mice. The data indicatethatp53 haplodeficiency affects the genotoxicity of NRTIs; thus, p53(+/-) mice may be a sensitive model for evaluating the carcinogenicity of perinatal exposure to NRTIs. Environ. Mol. Mutagen. 48:270-282, 2007. Published 2007 Wiley-Liss, Inc.
引用
收藏
页码:270 / 282
页数:13
相关论文
共 51 条
[1]   STATISTICAL TEST FOR THE COMPARISON OF SAMPLES FROM MUTATIONAL SPECTRA [J].
ADAMS, WT ;
SKOPEK, TR .
JOURNAL OF MOLECULAR BIOLOGY, 1987, 194 (03) :391-396
[2]   Nonclinical toxicology studies with zidovudine: Genetic toxicity tests and carcinogenicity bioassays in mice and rats [J].
Ayers, KM ;
Clive, D ;
Tucker, WE ;
Hajian, G ;
deMiranda, P .
FUNDAMENTAL AND APPLIED TOXICOLOGY, 1996, 32 (02) :148-158
[3]   Zidovudine: A review of its use in the management of vertically-acquired pediatric HIV infection [J].
Bhana N. ;
Ormrod D. ;
Perry C.M. ;
Figgitt D.P. .
Pediatric Drugs, 2002, 4 (8) :515-553
[4]   Oxidative DNA damage in fetal tissues after transplacental exposure to 3′-azido-3′-deoxythymidine (AZT) [J].
Bialkowska, A ;
Bialkowski, K ;
Gerschenson, M ;
Diwan, BA ;
Jones, AB ;
Olivero, OA ;
Poirier, MC ;
Anderson, LM ;
Kasprzak, S ;
Sipowicz, MA .
CARCINOGENESIS, 2000, 21 (05) :1059-1062
[5]   Molecular insights into NRTI inhibition and mitochondrial toxicity revealed from a structural model of the human mitochondrial DNA polymerase [J].
Bienstock, RJ ;
Copeland, WC .
MITOCHONDRION, 2004, 4 (2-3) :203-213
[6]   CELLULAR-METABOLISM OF (-) ENANTIOMERIC 2'-DEOXY-3'-THIACYTIDINE [J].
CAMMACK, N ;
ROUSE, P ;
MARR, CLP ;
REID, PJ ;
BOEHME, RE ;
COATES, JAV ;
PENN, CR ;
CAMERON, JM .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (10) :2059-2064
[7]   SOFTWARE FOR THE ANALYSIS OF MUTATIONS AT THE HUMAN HPRT GENE [J].
CARIELLO, NF .
MUTATION RESEARCH, 1994, 312 (02) :173-185
[8]  
Chumakov PM, 2000, BIOCHEMISTRY-MOSCOW+, V65, P28
[9]   REDUCTION OF MATERNAL-INFANT TRANSMISSION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 WITH ZIDOVUDINE TREATMENT [J].
CONNOR, EM ;
SPERLING, RS ;
GELBER, R ;
KISELEV, P ;
SCOTT, G ;
OSULLIVAN, MJ ;
VANDYKE, R ;
BEY, M ;
SHEARER, W ;
JACOBSON, RL ;
JIMENEZ, E ;
ONEILL, E ;
BAZIN, B ;
DELFRAISSY, JF ;
CULNANE, M ;
COOMBS, R ;
ELKINS, M ;
MOYE, J ;
STRATTON, P ;
BALSLEY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (18) :1173-1180
[10]  
COPELAND WC, 1992, J BIOL CHEM, V267, P21459